STAT Plus: Corbus shares will soar or dive soon. Here’s why
Adam’s Biotech Scorecard
Adam’s Biotech Scorecard is a subscriber-only newsletter offering unfiltered analysis from Adam Feuerstein, a veteran reporter with decades of experience covering the intersection of Wall Street and biotechnology. It’s delivered on Thursday mornings, and STAT+ subscribers can sign up here.
Latest
STAT Plus: Can iTeos and GSK solve TIGIT’s troubles?
STAT Plus: Thoughts, takes, and burning biotech questions as the beginning of the end of the year approaches
STAT Plus: The business of CRISPR’d medicine: Not great
STAT Plus: A strong start for Madrigal’s MASH drug launch
STAT Plus: On Andrew Left and the government’s fraud case
STAT Plus: A preview of Neurocrine’s muscarinic drug readout
STAT Plus: Novartis not ready to admit a $3 billion mistake
All Coverage